Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Finished Goods: 2013-2018

Historic Finished Goods for Theravance Biopharma (TBPH) over the last 5 years, with Sep 2018 value amounting to $3.5 million.

  • Theravance Biopharma's Finished Goods fell 22.92% to $3.5 million in Q3 2018 from the same period last year, while for Sep 2018 it was $3.5 million, marking a year-over-year decrease of 22.92%. This contributed to the annual value of $5.0 million for FY2017, which is 42.80% up from last year.
  • Per Theravance Biopharma's latest filing, its Finished Goods stood at $3.5 million for Q3 2018, which was down 11.76% from $4.0 million recorded in Q2 2018.
  • Over the past 5 years, Theravance Biopharma's Finished Goods peaked at $7.5 million during Q3 2014, and registered a low of $2.0 million during Q2 2017.
  • For the 3-year period, Theravance Biopharma's Finished Goods averaged around $3.6 million, with its median value being $3.5 million (2016).
  • In the last 5 years, Theravance Biopharma's Finished Goods crashed by 58.75% in 2016 and then surged by 99.60% in 2018.
  • Over the past 5 years, Theravance Biopharma's Finished Goods (Quarterly) stood at $5.6 million in 2014, then slumped by 43.71% to $3.1 million in 2015, then increased by 12.44% to $3.5 million in 2016, then soared by 42.80% to $5.0 million in 2017, then dropped by 22.92% to $3.5 million in 2018.
  • Its Finished Goods was $3.5 million in Q3 2018, compared to $4.0 million in Q2 2018 and $4.6 million in Q1 2018.